Clinical Trial

Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Study acronym: AFAN
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This research study is a phase Ib/II, single-arm, non-randomized, non-blind, multicenter study designed to determine whether Afatinib is effective and safe in patients with locoregionally unresectable and / or metastatic HNSCC with Fanconi Anemia. The main hypothesis, based on preclinical evidence, is that treatment with afatinib, an epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), could be an effective treatment option to control cancer for patients with FA - HNSCC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-17; most recent amendment 2026-05-22.
Status change: Not Yet Recruiting → Recruiting 2024-11-18
Trial Details
NCT Number NCT06648096
Lead Sponsor Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborators: MFAR Clinical Research S.L.
Conditions Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
Enrollment 25 participants
Start Date 2024-11-08
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-27